Many patients with RA are switched to another TNF inhibitor after first-line TNFi failure, even though second-line TNFi treatment has inferior persistence compared to a switch to non-TNFi treatment, Australian data show. A retrospective review of RA treatment patterns in 7740 patients in the OPAL dataset between 2010-2017 found that half (49%) of the 6914 ...
OPAL reveals variations in persistence with second line RA treatment
By Michael Woodhead
11 Dec 2019